Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Ciclesonide Nasal Aerosol vs Spray in PAR
NCT01654536Phase 4Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Sep 2012
- Primary completion
- Jul 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ciclesonide in perennial allergic rhinitis (PAR) (2 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Number of Subjects Experiencing Nasal Mucosal Disorders, Septum Disorders, or Nasal Septum Perforations at 6 months and Percentage of Subjects Experiencing Nasal Mucosal Disorders, Septum Disorders, or Nasal Septum Perforations at 6 months. Started Sep 2012; status: completed.
02
Drugs
ciclesonide
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT01654536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01654536.